Akribion Therapeutics has exited stealth mode and completed a seed financing round, raising €8 million to accelerate the development of novel therapeutics.  The round was led by CARMA FUND and RV Invest, with investments from MP Beteiligungs, Hessen Kapital I, Bruker Invest and High-Tech Gründerfonds.  Akribion is developing an RNA-guided, nuclease-based technology for programmable cell […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!